COMPANY PROFILE

CoMentis

Explore full profile

Privately held biopharmaceutical company focused on discovering and developing therapeutics

South San Francisco, United StatesFounded 2006Biotech & Life Sciences

Valuation $100–250M Last recorded · 2008

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About CoMentis

A digital assessment platform for identifying and supporting vulnerable customers in the financial and healthcare sectors. The company's solution helps organizations meet their duty of care obligations by using a proprietary framework that aligns with the FCA's four drivers of vulnerability. The platform is designed to be integrated into existing workflows, allowing businesses to proactively identify at-risk individuals and provide them with the necessary support.

Comentis primarily serves businesses in the consumer finance, automotive finance, and healthcare industries. The company's business model is based on providing its software as a service (SaaS) to these organizations. By using the Comentis platform, companies can enhance their compliance processes, improve customer outcomes, and reduce the risks associated with customer vulnerability.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2006
Headquarters: South San Francisco, United States
Employees: 21
Open positions: None listed
Dealroom signal: 59.7/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

5 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES DOther financing	Jun 2008	$20M	$80M	Muralitharan Kengatharan · John Higgins · Sanderling Ventures · Medicxi	—
SERIES COther financing	Dec 2007	$12M	$48M	Undisclosed	—

Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

CoMentis website traffic

Latest recorded traffic for CoMentis is 250 monthly website visits. CoMentis's team grew 0% over the past year.

Latest monthly visits250 1-year team growth0%

Monthly website visitsApr 2016–Oct 2023

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
SBSilvia BioCellular analysis and media for biomanufacturing optimization.	Sheffield, United Kingdom	Operational	4	$3.1M	$663K
MLMitotype Precision LabsHigh-throughput mitochondrial assays for drug discovery	Sheffield, United Kingdom	Operational
DTDraig TherapeuticsTargeted neuromodulators for major neuropsychiatric disorders treatment	Cardiff, United Kingdom	Operational
EPEpitopeaTransatlantic cancer immunotherapeutics company	Montreal, Canada	Operational
MBMyricx BioNovel antibody-drug conjugate payloads for cancer treatment	London, United Kingdom	Acquired
SHSiPhox HealthSiPhox Inc. offers a handheld testing device with RNA/DNA and protein testing for point-of-care and At-Home solutions	Burlington, United States	Operational
MTMyris TherapeuticsA transformational platform company that develops next-generation nanoarmored protein-polymer conjugates	Pittsburgh, United States	Operational
LBLeucid BioNext-generation CAR-T cell therapies for refractory cancers	London, United Kingdom	Operational